<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04520178</url>
  </required_header>
  <id_info>
    <org_study_id>18.1268-Aim 2</org_study_id>
    <nct_id>NCT04520178</nct_id>
  </id_info>
  <brief_title>Effects of 5HTP on the Injured Human Spinal Cord</brief_title>
  <acronym>5-HTP only</acronym>
  <official_title>Effects of the Serotonin Precursor, 5-hydroxytryptophan, in the Injured Human Spinal Cord</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess how the serotonin precursor, 5-HTP, alter nervous system excitability&#xD;
      and motor function in individuals with spinal cord injuries of differing chronicity and&#xD;
      severity. Participants will visit the lab on 4 separate occasions where they will be&#xD;
      administered four different drugs in a randomized, double-blinded, placebo-controlled&#xD;
      crossover design.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in motoneuron excitability</measure>
    <time_frame>Pre drug-intake, 30minutes, 60minutes, 90minutes and 120minutes post drug-intake</time_frame>
    <description>F waves</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in spinal excitability</measure>
    <time_frame>Pre drug-intake, 30minutes, 60minutes, 90minutes and 120minutes post drug-intake</time_frame>
    <description>H reflex</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in flexor reflex/spasms</measure>
    <time_frame>Pre drug-intake, 30minutes, 60minutes, 90minutes and 120minutes post drug-intake</time_frame>
    <description>Cutaneomuscular reflex</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in functional movement performance</measure>
    <time_frame>Pre drug-intake, 120-150minutes post drug-intake</time_frame>
    <description>Leg cycling task</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum analysis of 5HIAA</measure>
    <time_frame>90-120minutes post drug-intake</time_frame>
    <description>5-HIAA (serum)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum analysis of serotonin</measure>
    <time_frame>90-120minutes post drug-intake</time_frame>
    <description>5-HT (serum and whole blood), cortisol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum analysis of cortisol</measure>
    <time_frame>90-120minutes post drug-intake</time_frame>
    <description>serum cortisol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole blood analysis of Serotonin</measure>
    <time_frame>90-120minutes post drug-intake</time_frame>
    <description>Blood 5HT</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Spinal Cord Injuries</condition>
  <arm_group>
    <arm_group_label>Low-dose 5HTP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50mg 5-HTP in combination with 50mg carbidopa</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose 5HTP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100mg 5-HTP in combination with 50mg carbidopa</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbidopa</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>50mg carbidopa only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Hydroxytryptophan 100 MG</intervention_name>
    <description>100mg combined with 50mg carbidopa</description>
    <arm_group_label>High-dose 5HTP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Hydroxytryptophan</intervention_name>
    <description>50mg combined with 50mg carbidopa</description>
    <arm_group_label>Low-dose 5HTP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbidopa</intervention_name>
    <description>50mg</description>
    <arm_group_label>Carbidopa</arm_group_label>
    <arm_group_label>High-dose 5HTP</arm_group_label>
    <arm_group_label>Low-dose 5HTP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  participants must have suffered trauma to the spinal cord at least six months ago or&#xD;
             longer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  individuals with damage to the nervous system other than to the spinal cord&#xD;
&#xD;
          -  pregnant and/or breastfeeding women&#xD;
&#xD;
          -  alcoholic participants&#xD;
&#xD;
          -  history of seizure/epilepsy&#xD;
&#xD;
          -  history of suicidal thoughts or behaviors&#xD;
&#xD;
          -  known or suspected allergy to the medication ingredients&#xD;
&#xD;
          -  cardiovascular disease including history of heart attack or heart rhythm&#xD;
             irregularities&#xD;
&#xD;
          -  coronary artery disease&#xD;
&#xD;
          -  reduced liver function or disease&#xD;
&#xD;
          -  reduced kidney function or disease&#xD;
&#xD;
          -  lung disease&#xD;
&#xD;
          -  comatose or depressed states due to CNS depressants&#xD;
&#xD;
          -  endocrine dysfunction&#xD;
&#xD;
          -  blood dyscrasias or blood related disease&#xD;
&#xD;
          -  bone marrow depression&#xD;
&#xD;
          -  hypocalcemia&#xD;
&#xD;
          -  history of stomach ulcers&#xD;
&#xD;
          -  wide angle glaucoma&#xD;
&#xD;
          -  phenylketonuria&#xD;
&#xD;
          -  history of tumors&#xD;
&#xD;
          -  uncontrolled heart problems&#xD;
&#xD;
          -  unstable psychiatric or mental disorder&#xD;
&#xD;
        Participants taking:&#xD;
&#xD;
          -  monoamine oxidase inhibitor therapy&#xD;
&#xD;
          -  serotonergic antidepressants&#xD;
&#xD;
          -  tricyclic antidepressants&#xD;
&#xD;
          -  any type of serotonergic agonist&#xD;
&#xD;
          -  dopamine D2 receptor antagonists&#xD;
&#xD;
          -  amphetamine&#xD;
&#xD;
          -  CNS depressants&#xD;
&#xD;
          -  levodopa&#xD;
&#xD;
          -  lithium&#xD;
&#xD;
          -  anti-hypertensive drugs&#xD;
&#xD;
          -  iron salts&#xD;
&#xD;
          -  metoclopramide&#xD;
&#xD;
          -  phenothiazine medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica D'Amico, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica D'Amico, PhD</last_name>
    <phone>5025827443</phone>
    <email>jessica.damico@louisville.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Louisville, Kentucky Spinal Cord Injury Research Centre</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica D'Amico, PhD</last_name>
      <phone>502-582-7443</phone>
      <email>jessica.damico@louisville.edu</email>
    </contact>
    <investigator>
      <last_name>David Rouffet, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 17, 2020</study_first_submitted>
  <study_first_submitted_qc>August 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Louisville</investigator_affiliation>
    <investigator_full_name>Jessica M D'Amico</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>5-Hydroxytryptophan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

